AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8715-8721

  Polverino, Anthony ^a   Coxon, Angela ^a   Starnes, Charlie ^a   Diaz, Zobedia ^a   DeMelfi, Thomas ^a   Wang, Ling ^a   Bready, James ^a   Estrada, Juan ^a   Cattley, Russell ^a   Kaufman, Stephen ^a   Chen, Danlin ^a   Gan, Yongmei ^a   Kumar, Gondi ^a   Meyer, James ^a   Neervannan, Sesha ^a   Alva, Gonzalo ^a   Talvenheimo, Jane ^a   Montestruque, Silvia ^a   Tasker, Andrew ^a   Patel, Vinod ^a   Radinsky, Robert ^a   Kendall, Richard ^a   more..

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; FIBROBLAST GROWTH FACTOR; N (2,3 DIHYDRO 3,3 DIMETHYL IH INDOL 6 YL) 2 [(4 PYRIDINYLMETHYL)AMINO] 3 PYRIDINECARBOXAMIDE; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; NICOTINAMIDE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CANCER INHIBITION; CANCER REGRESSION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EPIDERMOID TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE; CELL LINE, TUMOR; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLASTS; HUMANS; INDOLES; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MICE; MICE, NUDE; NIACINAMIDE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SKIN; TRANSPLANTATION, HETEROLOGOUS; UMBILICAL VEINS;

EID: 33749000911     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4665     Document Type: Article

References (21)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-95.
2. Scappaticci FA. Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 2002;20:3906-27.
3. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
4. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol 2005;7:870-9.
5. Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002;20:1692-703.
6. Alitalo K, Carmeliet P. Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002;1:219-27.
7. Hurwitz H, Dowlati A, Savage S, et al. Safety, tolerability, and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005;23:3012.
8. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005;23:3002.
9. Thomas AL, Morgan B, Horsfield MA, et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005;23:4162-71.
10. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
11. Demetri GD, van Oosterom AT, Blackstein M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients following failure of imatinib for metastatic GIST. J Clin Oncol 2005;23:4000.
12. Eisen T, Ahmad T, Gore ME, et al. Phase I trial of BAY 43-9006 (sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients. J Clin Oncol 2005;23:7508.
13. Rini R, Rixe O, Bukowski R, et al. AG-013736, a multitarget tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell carcinoma (RCC). J Clin Oncol 2005;23:4509.
14. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol 2005;23:4.
15. Miller KD, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur J Cancer Suppl 2005;3:275.
16. Herbst R, Kuzrock R, Parson M, et al. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) of AMG 706 in patients (pts) with advanced solid tumors. Eur J Cancer Suppl 2005;3:1455.
17. Rosen L, Kurzrock R, Jackson E, et al. Safety and pharmacokinetics of AMG 706 in patients with advanced solid tumors. J Clin Oncol 2005;23:195.
18. Askew B, Adams J, Booker S, et al. Amgen, Inc., Assignee. Substituted alkylamine derivatives and methods of use. U.S. patent 6,878,714, 2005.
19. Miles AA, Miles EM. Vascular reactions to histamine, histamine-liberator, and leukotaxine in the skin of guinea pigs. J Physiol 1952;118:228-57.
20. Coxon A, Bolon B, Estrada J, et al. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis Rheum 2002;46:2604-12.
21. Beckstead JH. A simple technique for preservation of fixation-sensitive antigens in paraffin-embedded tissues. J Histochem Cytochem 1994;42:1127-34.